Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a subsidiary) on October 20, 2016. The filing details corporate governance actions taken on this date, including the approval of executive compensation plans and the results of the Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on governance and compensation structures rather than financial performance data.
Material Changes and Corporate Actions
- Long-Term Incentive Plan (LTIP): The Board approved a plan for fiscal year 2019 where bonuses are tied to Return on Invested Capital (ROIC). ROIC is calculated as EBIT divided by the sum of average consolidated debt and average stockholders' equity. Target bonus amounts range from 18% to 69% of base salaries for participating officers.
- Restricted Stock Units (RSUs): The Board granted RSUs to four executives, vesting 50% on the first anniversary and 50% on the second anniversary:
- Molly Hemmeter (CEO): 47,406 RSUs
- Gregory Skinner (CFO): 17,826 RSUs
- Ronald Midyett (COO): 14,290 RSUs
- Larry Hiebert (President, Lifecore Biomedical): 13,250 RSUs
- Annual Meeting Results:
- Director Election: Four Class 1 directors were elected with significant majority support (e.g., Catherine A. Sohn received 20,792,582 votes for).
- Auditor Ratification: Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending May 28, 2017 (25,585,650 votes for).
- Executive Compensation: The non-binding advisory proposal was approved (20,355,665 votes for).
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on market outlook, or specific risk factors. The primary contingency noted is that eligibility for the LTIP bonuses is subject to the participating employees remaining employed through the last day of fiscal year 2019.
Investor Verification Checklist
- Verify the distinction between the parent company (Landec Corporation) and the subsidiary (Lifecore Biomedical, Inc.) regarding the scope of the RSU grants.
- Review the specific ROIC targets and EBIT calculations for fiscal year 2019 to understand the potential payout magnitude of the new LTIP.
- Confirm the vesting schedules and potential dilution impact of the 92,772 total RSUs granted to executives.
- Check subsequent filings for the actual fiscal year 2019 financial results to determine if the ROIC targets were met.